AstraZeneca Plc, the U.K.’s second-largest drugmaker, agreed to buy ZS Pharma of California for $2.7 billion in cash to gain a potential blockbuster medicine for a deadly condition.
ZS Pharma holders will get $90 per share, London-based AstraZeneca said in a statement. ZS Pharma’s board agreed to the transaction.
To contact the reporter on this story: Marthe Fourcade in Paris at mfourcade@bloomberg.net To contact the editors responsible for this story: Chitra Somayaji at csomayaji@bloomberg.net David Whitehouse